Jerrold B. Grossman - Aug 29, 2024 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
Director
Signature
/s/ Dr. Jerrold B. Grossman, by Adam S. Grossman as Attorney-in-fact
Stock symbol
ADMA
Transactions as of
Aug 29, 2024
Transactions value $
-$2,363,932
Form type
4
Date filed
8/30/2024, 09:02 PM
Previous filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Options Exercise $435K +119K +25.44% $3.66 586K Aug 29, 2024 Direct
transaction ADMA Common Stock Options Exercise $53.6K +9K +1.54% $5.96 595K Aug 29, 2024 Direct
transaction ADMA Common Stock Options Exercise $97.2K +9K +1.51% $10.80 604K Aug 29, 2024 Direct
transaction ADMA Common Stock Sale -$2.36M -137K -22.65% $17.27 467K Aug 29, 2024 Direct F1, F2
holding ADMA Common Stock 22.9K Aug 29, 2024 See Footnote F3
holding ADMA Common Stock 31.4K Aug 29, 2024 See Footnote F4
holding ADMA Common Stock 38.3K Aug 29, 2024 See Footnote F5
holding ADMA Common Stock 175 Aug 29, 2024 See Footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Common Stock Options Exercise -$435K -119K -100% $3.66 0 Aug 29, 2024 Common Stock 119K $3.66 Direct F7
transaction ADMA Common Stock Options Exercise -$53.6K -9K -100% $5.96 0 Aug 29, 2024 Common Stock 9K $5.96 Direct F8, F10
transaction ADMA Common Stock Options Exercise -$97.2K -9K -100% $10.80 0 Aug 29, 2024 Common Stock 9K $10.80 Direct F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2 Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 455,285 shares of common stock owned by the reporting person.
F3 These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.
F4 These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
F5 These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis.
F6 These shares are owned by the reporting person's wife.
F7 These options were granted on June 6, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019.
F8 These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.
F9 These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017.
F10 The Reporting Person is exercising these options due, in part, to their near-term expiration date.

Remarks:

Exhibit 24 - Power of Attorney